17:38 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Aimovig approved in Europe for migraine prevention

Novartis AG (NYSE:NVS; SIX:NOVN) said the European Commission approved Aimovig erenumab to prevent migraines in adults experiencing four or more per month. According to the pharma, the drug is the first calcitonin gene-related peptide (CGRP)...
22:41 , Jul 30, 2018 |  BC Extra  |  Company News

Aimovig approved in Europe for migraine prevention

Novartis AG (NYSE:NVS; SIX:NOVN) said Monday the European Commission approved Aimovig erenumab to prevent migraines in adults experiencing four or more per month. According to the pharma, the drug is the first calcitonin gene-related peptide...
18:26 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Teva discontinues Phase III chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the...
19:59 , Jun 15, 2018 |  BC Week In Review  |  Company News

ICER panel says long-term value for Aimovig for migraines is intermediate

ICER's California Technology Assessment Forum (CTAF) voted that the long-term value of calcitonin gene-related peptide (CGRP) inhibitor Aimovig erenumab for patients with chronic migraine who had previously failed other preventative migraine treatments was intermediate, while...
19:07 , Jun 15, 2018 |  BC Extra  |  Clinical News

Teva discontinues chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the...
20:40 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the...
21:23 , Jun 11, 2018 |  BC Extra  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule...
18:29 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

CHMP recommendations include Aimovig, orphan candidates

Among a host of positive recommendations announced on June 1, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin...
23:11 , Jun 7, 2018 |  BC Week In Review  |  Company News

ICER updates cost-effectiveness estimates for CGRP inhibitors for migraines

ICER released an evidence report May 31 evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses...
22:08 , Jun 1, 2018 |  BC Extra  |  Company News

Aimovig price improves ICER's migraine outlook

ICER released an evidence report evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses using the...